Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.030
Buy
RSI(14)
51.379
Neutral
STOCH(KDJ)(9,3,3)
51.509
Neutral
ATR(14)
0.114
High Vlolatility
CCI(14)
-33.043
Neutral
Williams %R
64.706
Sell
TRIX(12,20)
0.386
Sell
StochRSI(14)
0.000
Sell
Search
Compugen Ltd
CGENAdd to Watchlist
2.355USD
-0.065-2.69%
Close 07-23 16:00（ET）Quotes delayed by 15 min
222.67MMarket Cap
6.28P/E TTM
View Detailed Chart
TradingKey ChartIntraday
1m
30m
1h
D
W
M
D
Today
-2.69%
5 Days
+1.07%
1 Month
+16.58%
6 Months
+12.68%
Year to Date
+53.92%
1 Year
+50.00%
Key Figures
2.390Open
2.400High
174.54KVolume
6.28P/E TTM
LossP/E Dynamic
--Dividend TTM
0.18%Turnover Ratio
2.420Prev. Close
2.325Low
265.80KTurnover
LossP/E Static
2.17P/B
0.00%Div Yield TTM
26.03%ROA
3.23552wk High
0.70Volume Ratio
-14.23MNet Profit
94.55MShares
0.3750EPS TTM
2.77Beta
44.84%ROE
1.29552wk Low
3.10%Amplitude
16.18%Gross Margin
222.67MMarket Cap
5.25Reward/Risk
3.88%Risk Rate
TradingKey Stock Score of Compugen Ltd
Currency: USD Updated: 2026-07-23Key Insights
Compugen Ltd's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 148 out of 386 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 4.60.In the medium term, the stock price is expected to trend down.Despite a strong stock market performance and outperforming fundamentals over the past month, the technicals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Compugen Ltd's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Compugen Ltd Highlights
StrengthsRisks
Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 117.47% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 72.76M.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Overvalued
The company’s latest PE is 6.24, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 13.75M shares, increasing 3.14% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 811.59K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.33.
Analyst Rating
Based on
5
analysts
Strong Buy
Current Rating
4.600
Target Price
+84.74%
Upside Space
Compugen Ltd News
More news coming soon, stay tuned...
Earnings Forecast
Analyst Rating
Based on
5
analysts
Strong Buy
Current Rating
4.600
Target Price
+84.74%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
495
Total
6
Median
7
Average
Company name
Ratings
Analysts
Compugen Ltd
CGEN
5
Beigene Ltd
ONC
28
argenx SE
ARGX
27
Ionis Pharmaceuticals Inc
IONS
26
IQVIA Holdings Inc
IQV
25
Insmed Inc
INSM
23
1
2
3
...
99
Indicators
Moving Average
Indicators
Value
Direction
MA5
2.392
Sell
MA10
2.364
Sell
MA20
2.305
Buy
MA50
2.351
Buy
MA100
2.400
Sell
MA200
2.064
Buy
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Compugen Ltd Info
Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.
Ticker SymbolCGEN
CompanyCompugen Ltd
CEOOphir (Eran)
Websitehttps://cgen.com/
Shareholders
Related Instruments
+1.95%
+1.46%
-0.85%
+1.43%
+2.37%
+2.01%
+1.49%
+0.38%
0.00%
+0.71%
+1.27%
+0.15%
-0.94%
-0.03%
+1.31%
0.00%
+0.11%
+8.61%
-0.21%
+2.45%Popular Instruments
51915.200
+191.200 (+0.37%)
28490.600
-87.400 (-0.31%)
7425.100
+5.200 (+0.07%)
14992.000
-109.000 (-0.72%)
64977.000
-394.000 (-0.60%)
6245.200
+29.500 (+0.47%)
89.363
-2.749 (-2.98%)
321.680
-4.210 (-1.29%)
208.770
-3.290 (-1.55%)
4060.510
+11.140 (+0.28%)
FAQs
What is the current price of Compugen Ltd (CGEN)?
The current price of Compugen Ltd (CGEN) is 2.35.
What is the symbol of Compugen Ltd?
The ticker symbol of Compugen Ltd is CGEN.
What is the 52-week high of Compugen Ltd?
The 52-week high of Compugen Ltd is 3.23.
What is the 52-week low of Compugen Ltd?
The 52-week low of Compugen Ltd is 1.29.
What is the market capitalization of Compugen Ltd?
The market capitalization of Compugen Ltd is 222.67M.
Is Compugen Ltd (CGEN) currently rated as Buy, Hold, or Sell?
According to analysts, Compugen Ltd (CGEN) has an overall rating of STRONG BUY, with a price target of 4.60.
What is the Earnings Per Share (EPS TTM) of Compugen Ltd (CGEN)?
The Earnings Per Share (EPS TTM) of Compugen Ltd (CGEN) is 0.38.